Nicholas Turner
Breast cancer researcher who turned ctDNA into a tool for choosing treatment, leading SERENA-6 and CAPItello-291.
Nicholas Turner leads the Ralph Lauren Centre for Breast Cancer Research and has driven ctDNA-guided treatment switching (SERENA-6, plasmaMATCH) and the capivasertib programme (CAPItello-291) in HR-positive breast cancer.
| Title | Journal | Year |
|---|---|---|
| Capivasertib in hormone receptor-positive advanced breast cancer (CAPItello-291) | NEJM | 2023 |
| Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH) | Lancet Oncology | 2020 |
Pages like this
not linked directly; found by shared links- IdeaMolecular-progression switching beyond ESR1
Shares Camizestrant, SERENA-6, Capivasertib, Liquid biopsy (ctDNA).
- TermESR1 mutation
Shares Camizestrant, SERENA-6, Estrogen receptor (ERα), Liquid biopsy (ctDNA).
- PairingOral SERD + CDK4/6 inhibitor after ESR1 emergence
Shares Camizestrant, SERENA-6, HR-positive / HER2-negative breast cancer.
- TrialCAPItello-281
Shares Capivasertib, AKT.
- TrialCAMBRIA-1 & CAMBRIA-2
Shares Camizestrant, HR-positive / HER2-negative breast cancer.
- PairingPI3K/AKT-pathway inhibitor + endocrine therapy (± CDK4/6)
Shares Capivasertib, AKT, HR-positive / HER2-negative breast cancer.
- TermOral SERD
Shares Camizestrant, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- PersonAnn H. Partridge
Shares Breast Cancer Research Foundation, HR-positive / HER2-negative breast cancer.